P2 purinergic receptor (P2R) (P2R)

The P2 purinergic receptor family comprises a diverse group of cell surface receptors activated by extracellular nucleotides, including ATP, ADP, UTP, and UDP [1]. These receptors are categorized into two main subfamilies: P2X receptors, which function as ligand-gated ion channels, and P2Y receptors, which are G protein-coupled receptors [2]. They are ubiquitously expressed and mediate a wide array of physiological functions such as platelet aggregation, neurotransmission, smooth muscle contraction, and immune modulation [3]. In clinical practice, P2 receptors are major therapeutic targets, most notably the P2Y12 receptor, which is the target for essential antiplatelet medications used to prevent myocardial infarction and stroke [4]. Beyond cardiovascular health, the P2 family is increasingly investigated for roles in chronic pain, inflammation, and respiratory diseases, with P2X3 antagonists recently gaining approval for chronic cough [1, 5]. The structural diversity within this family allows for highly specific pharmacological interventions, though challenges remain regarding off-target effects and systemic safety [2]. These receptors also play significant roles in the tumor microenvironment, where ATP signaling can modulate immune evasion and cancer progression [1]. Overall, the P2 receptor family represents a critical node in purinergic signaling with broad implications for human health and disease management.

Other names

PurinoceptorP2 receptor familyNucleotide receptorATP receptor

Drugs targeting the P2 receptor family primarily act as antagonists to inhibit specific signaling pathways. For example, P2Y12 receptor antagonists (e.g., clopidogrel) block ADP-induced platelet activation by preventing the inhibition of adenylyl cyclase [4]. P2X3 receptor antagonists (e.g., gefapixant) inhibit ATP-gated ion channels on sensory neurons to reduce hypersensitivity in conditions like chronic cough [5].